Ask AI
ProCE Banner Series

Year in Review in EGFR-Mutated NSCLC: Impact of Recent Advances Across the Disease Continuum

This educational activity will provide a practical update on the evolving treatment landscape for EGFR-mutant NSCLC, spanning nonmetastatic disease, first-line therapy selection, and emerging strategies to overcome resistance in previously treated patients. Join us to review the latest clinical evidence, guideline-driven care approaches, and key decision-making considerations that can help inform treatment in practice.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational activity is intended for oncologists, pathologists, nurses, pharmacists, physician associates, and other health care professionals who identify, treat, and manage patients with locally advanced EGFRm non-small lung cancer.

All Events

Year in Review in EGFR-Mutated NSCLC: Impact of Recent Advances Across the Disease Continuum

Upcoming Events

May

19

2026

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
To improve learners’ knowledge, confidence, and competence in applying recent EGFR testing and treatment advances in EGFRm NSCLC.

Target Audience
This educational activity is intended for oncologists, pathologists, nurses, pharmacists, physician associates, and other health care professionals who identify, treat, and manage patients with locally advanced EGFRm non-small lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate current guideline-based recommendations to select appropriate biomarker testing strategies for patients with suspected or confirmed EGFR-mutated NSCLC, including less common alterations

  • Design individualized treatment plans for patients with EGFR exon 19 or 21 alterations in the perioperative and metastatic settings by integrating the latest clinical trial data and guideline-endorsed sequencing strategies

  • Evaluate and compare the safety profiles, efficacy, and treatment burden of first-line regimens to guide shared decision-making aligned with patient preferences and risk features

  • Incorporate the latest clinical evidence on novel and emerging therapies into treatment decisions for patients with EGFR exon 20 insertions or other non-classical EGFR mutations

  • Adapt management strategies for patients with acquired resistance to EGFR TKIs by assessing biomarker-driven mechanisms and selecting subsequent lines of therapy supported by trial-based evidence and expert consensus.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-257-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. 

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS). 

IPCE Credit Designation

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/657115052be04.jpg

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191